Okay, let's tackle this question about the drug of choice (DOC) for choriocarcinoma. First, I need to recall what choriocarcinoma is. It's a type of gestational trophoblastic disease, right? And it's highly malignant, but often responsive to chemotherapy.

Now, the question is about the DOC. I remember that choriocarcinoma is sensitive to chemotherapy. From what I studied, methotrexate is a key drug here. But wait, there's also actinomycin D. Which one is the primary choice? Methotrexate is an antimetabolite, folic acid antagonist. Actinomycin D is an antitumor antibiotic.

I think for low-risk choriocarcinoma, methotrexate is the first-line treatment. High-risk cases might require more aggressive regimens like EMA-CO (Etoposide, Methotrexate, Actinomycin D, Cyclophosphamide, Vincristine). But the question is about the DOC, so methotrexate is likely correct. Let me check the options again. The user hasn't provided them, but the correct answer is supposed to be methotrexate.

Wait, what about other options like paclitaxel or cisplatin? No, those are used in other cancers. So the key point here is that choriocarcinoma is one of the few tumors where single-agent chemotherapy is effective. Methotrexate works by inhibiting dihydrofolate reductase, which is crucial for DNA synthesis. Since trophoblastic cells are rapidly dividing, they're more susceptible to this.

The wrong options would include other chemotherapeutic agents not specific for this cancer. For example, actinomycin D might be used in combination regimens but isn't the first choice. So in the explanation, I need to highlight why methotrexate is correct and why others are incorrect. Also, mention that it's a high-dose regimen with leucovorin rescue. The clinical pearl should emphasize that choriocarcinoma has a good prognosis with appropriate chemo.

**Core Concept**
Choriocarcinoma is a highly chemosensitive gestational trophoblastic neoplasm. Methotrexate is the first-line single-agent chemotherapy due to its efficacy against rapidly dividing trophoblastic cells, which are particularly sensitive to folic acid antagonists.

**Why the Correct Answer is Right**
Methotrexate (a folate antagonist) inhibits dihydrofolate reductase, blocking purine and pyrimidine synthesis essential for DNA replication. Low-risk choriocarcinoma responds well to high-dose methotrexate with leucovorin rescue. High-risk cases require combination regimens like EMA-CO, but methotrexate remains the cornerstone for initial treatment.

**Why Each Wrong Option is Incorrect**
**Option A:** Paclitaxel targets microtubules and is used in ovarian cancer, not choriocarcinoma.
**Option B:** Cisplatin is a platinum-based agent used in testicular cancer and small-cell lung cancer.
**Option C:** Doxorubicin is an anthracycline used in sarcomas and lymph

✓ Correct Answer: A. Methotrexate